Recently, three immune-related gene expression signatures that predict clinical response to PD-1 blockade across multiple cancer types have been identified: the IFN-γ signature, the Expanded immune gene signature and the T-cell inflamed signature.22 Interestingly, patients rendering TR TIL products exhibited significantly higher scores for the three mentioned signatures, in particular for the T-cell inflamed GEP (Fig. 6c). This evidence concerns the gene PDCD1 and cancer.